Treatment of hyperlipoproteinemia type II with etofibrate.
Seven patients with hyperlipoproteinemia (HLP) type II (four patients with type II A and three patients with type II B), who were experienced to be resistant to hypolipidemic drugs, were treated for 6 months with etofibrate, a double-ester of nicotinic acid and clofibrinic acid, at a dose of 0.3 g t.i.d. Mean serum cholesterol level decreased by up to 18% from a pre-treatment value of 7.7 +/- 1.4 mmol/l. The reduction of serum cholesterol was due both to a decrease in very low density (VLDL) and low density (LDL) lipoprotein cholesteral by 61 and 25%, respectively (after 6 months). Furthermore alpha-LP (HDL) cholesterol increased by 8%, (after 6 months). All seven patients had previously received clofibrate and had obtained a mean decrease in plasma cholesterol by 6%. There was a slight transient increase in S-ASAT and S-ALAT simultaneous with in increase in serum urate. However, these values returned after 3 months to pre-treatment level. No influence on glucose tolerance was recorded. There were no bothersome side effects except a transient discomfort in the form of flushing or acid indigestion which occurred after 1--2 months of treatment with etofibrate.
D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002995:Clofibric Acid / Q000031:analogs & derivatives; D005951:Glucose Tolerance Test; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D008055:Lipids; D008074:Lipoproteins; D009539:Nicotinic Acids; C009746:etofibrate; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate